Special Issue "HIV Vaccines"

Quicklinks

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 July 2013)

Special Issue Editor

Guest Editor
Prof. Dr. Robin J. Shattock
Section of Infectious Diseases, Faculty of Medicine, Wright-Fleming Institute, St Mary's Campus, Imperial College, Norfolk Place, London W2 1PG, UK
Website: http://www1.imperial.ac.uk/medicine/people/r.shattock/
E-Mail: r.shattock@imperial.ac.uk
Interests: HIV vaccines, mucosal immunity, HIV prevention/transmission, immunogen discovery, vaccine delivery strategies, replicating and non-replicating vectors

Special Issue Information

Dear Colleagues,

HIV remains a major health problem of global concern. According to estimates from the World Health Organization, over 34 million people are infected with HIV, with 7000 new infections occurring daily and 1.7 million people dying of HIV in 2011. Although current anti-retroviral therapy provides highly effective treatment, for every person starting ART two people are newly infected with 20 million more people predicted to acquire HIV by 2031, increasing potential treatment costs up to $35 billion a year. Thus successful provision of universal treatment access may be critically dependent on reducing the number of new infections. Although other biomedical interventions have an important role in reducing HIV incidence, vaccines still provide the best hope for changing the epidemic. 30 years on from the discovery of HIV, a single HIV vaccine trial has shown modest efficacy of short duration. However, great advances have been made in the discovery of broadly neutralizing antibodies together with the ontogeny of their development. This combined with recent animal model data showing profound control of viral replication by replicating vectors heralds a new era in HIV vaccine research. This special issue on “HIV Vaccines” will explore how recent science is changing the prospects for developing effective vaccines able to provide protection from acquisition and control of infection. The issue will highlight leading developments in the vaccine technology, including but not limited to, induction of neutralizing antibodies, improvements in epitope design, use of replicating and non-replicating vectors, subunit vaccines (proteins/peptides/scaffolds) and DNA. Novel mechanisms of enhancing vaccine efficacy are also welcome including research on adjuvants and biomarkers of protection against HIV. The special issue will be a mix of original research articles, and mini reviews. The main focus of this special issue is to present cutting edge research and recent developments in vaccines, which can prevent HIV acquisition and disease progression.

Prof. Dr. Robin Shattock
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Keywords

  • replicating vectors and viral control
  • engaging the B cell germline
  • new molecular approaches for improving T cell potency
  • targeting functional trimers
  • mucosal immunity and HIV prevention
  • harnessing innate immunity against HIV acquisition
  • translating broadly neutralizing antibodies into effective prevention
  • prime-boost: a role for next generation DNA delivery/constructs
  • vector control: getting the best from recombinant-vector based vaccines
  • what’s needed to sustain protective antibody responses: novel adjuvant developments
  • experimental vaccine trials – the need for accelerated human immunogen discovery
  • therapeutic vaccine – can they contribute towards effective cure
  • correlates of protection: do they offer novel mechanisms for enhancing vaccine efficacy

Published Papers (8 papers)

by ,  and
Vaccines 2014, 2(1), 138-159; doi:10.3390/vaccines2010138
Received: 7 November 2013; in revised form: 8 February 2014 / Accepted: 10 February 2014 / Published: 25 February 2014
Show/Hide Abstract | PDF Full-text (405 KB) | HTML Full-text | XML Full-text

by  and
Vaccines 2014, 2(1), 15-35; doi:10.3390/vaccines2010015
Received: 29 October 2013; in revised form: 29 October 2013 / Accepted: 9 December 2013 / Published: 27 December 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (456 KB) | HTML Full-text | XML Full-text
abstract graphic

by ,  and
Vaccines 2014, 2(1), 1-14; doi:10.3390/vaccines2010001
Received: 16 October 2013; in revised form: 15 November 2013 / Accepted: 9 December 2013 / Published: 19 December 2013
Show/Hide Abstract | PDF Full-text (205 KB) | HTML Full-text | XML Full-text

by
Vaccines 2013, 1(4), 513-526; doi:10.3390/vaccines1040513
Received: 21 August 2013; in revised form: 14 October 2013 / Accepted: 17 October 2013 / Published: 30 October 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (363 KB) | HTML Full-text

by
Vaccines 2013, 1(4), 497-512; doi:10.3390/vaccines1040497
Received: 6 September 2013; in revised form: 11 October 2013 / Accepted: 12 October 2013 / Published: 28 October 2013
Show/Hide Abstract | PDF Full-text (580 KB) | HTML Full-text | XML Full-text

by  and
Vaccines 2013, 1(4), 481-496; doi:10.3390/vaccines1040481
Received: 5 September 2013; in revised form: 8 October 2013 / Accepted: 12 October 2013 / Published: 28 October 2013
Show/Hide Abstract | PDF Full-text (464 KB) | HTML Full-text | XML Full-text

by , , ,  and
Vaccines 2013, 1(3), 348-366; doi:10.3390/vaccines1030348
Received: 3 June 2013; in revised form: 25 July 2013 / Accepted: 5 August 2013 / Published: 14 August 2013
Show/Hide Abstract | PDF Full-text (510 KB) | HTML Full-text | XML Full-text

by ,  and
Vaccines 2013, 1(3), 328-342; doi:10.3390/vaccines1030328
Received: 5 June 2013; in revised form: 11 July 2013 / Accepted: 23 July 2013 / Published: 9 August 2013
Show/Hide Abstract | PDF Full-text (447 KB) | HTML Full-text | XML Full-text

Last update: 24 December 2012

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert